ARC Announces New Leadership Team member
Today we sat down virtually with the newest member of the ARC team, Vanessa Boulanger who has recently joined ARC as the Executive Director of Strategic Partnerships. Vanessa brings over 15 years of experience centering cross-sector collaboration in pursuit of...
Vutrisiran receives Fast Track Designation from FDA
Alnylam has submitted a new drug application (NDA) to the FDA for vutrisiran, which could bring another treatment option to patients with ATTR amyloidosis. Vutrisiran received “Fast Track” Designation, which is a process designed to expedite the review of drugs...
From weeks to live to pioneering the Amyloidosis landscape
ARC's CEO, Isabelle Lousada, was told she had just weeks to live when she was diagnosed with AL Amyloidosis 25 years ago. A dedicated team of physicians at Boston Medical Center performed an experimental stem cell transplant, making Isabelle only...
Report From the Amyloidosis Forum Scientific Workshop
The Amyloidosis Forum, a Public Private Partnership with ARC and FDA, hosted the workshop on 22nd January, as part of an ongoing process to develop novel endpoints for clinical trial in AL amyloidosis. In 2020, the Amyloidosis Forum launched a...
Managing GI Issues in Amyloidosis – FAQ
Dr. John Clarke from Stanford University presented in a recent ARC Talks webinar on Gastro Intestinal Disturbances and Symptom Relief for Amyloidosis. This report covers the most frequently asked questions and recommendations. (more…)